This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (4)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neurology, Other  • Alert me on articles by topic

Rationale for More Effective Therapies

Ahmet Höke, MD, PhD, FRCPC

Arch Neurol. 2006;63:1681-1685.

Most peripheral neuropathies are length dependent and result in distal axonal degeneration rather than loss of neuronal cell bodies. Available therapies for axonal peripheral neuropathies are designed to control painful symptoms and not to treat the underlying axonal degeneration. Many neuroprotective therapies are being developed, primarily for central nervous system disorders such as stroke or multiple sclerosis. However, strategies with the purpose of promoting survival of injured neurons (ie, preventing cell death) may not be applicable in many peripheral nervous system illnesses when the primary pathologic disorder that leads to symptoms is distal axonal degeneration. Neuronal cell death, if it occurs, is often a late event and may be untreatable in the near future. In contrast, distal axonal degeneration is an early event that may be amenable to treatment. Mechanistic studies that examine the axon-glia interaction and axonal biology are likely to yield novel therapeutic targets for peripheral neuropathies.

Author Affiliation: Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Md.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

WHAT IS NEXT IN ALS CLINICAL TRIALS?
Hoke et al.
Neurology 2008;70:1366-1367.
FULL TEXT  

Soluble Complement Receptor 1 Protects the Peripheral Nerve from Early Axon Loss after Injury
Ramaglia et al.
Am. J. Pathol. 2008;172:1043-1052.
ABSTRACT | FULL TEXT